Rituximab for OCD or psychosis linked to immune inflammation
Treatments studied
Part of Mental health clinical trials.
This trial tests rituximab (an immune system medicine) to see if it can reduce OCD symptoms and/or psychosis when there are signs the immune system may be involved. You may be considered if other standard psychiatric treatments have not helped enough and your illness seems relatively recent with possible inflammation clues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 55 years old
- You have OCD (or OCD-like symptoms) or a non–mood psychosis diagnosis like schizophrenia or delusional disorder
- Your symptoms are at least “moderately ill” on a doctor’s global severity rating
- You tried at least 2 standard psychiatric medicines at the highest tolerated doses for 6 months, but did not improve much
- Your psychiatric medicines have been unchanged for at least 1 month before starting
- You must have signs suggesting immune/inflammation involvement, such as infection-linked onset, MRI/EEG/CFS or blood evidence of inflammation/autoimmunity, or improvement after anti-inflammatory treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests ocrelizumab, a medicine that affects parts of the immune system, to see if it can improve psychosis symptoms in people with schizophrenia-spectrum disorders. It’s mainly for younger adults with ongoing psychosis and evidence that the symptoms began early in life, with certain infection/vaccine safety requirements.
This trial is testing a new medication that may reduce inflammation in the brain for people with schizophrenia. It focuses on those who have a specific immune marker, which might mean the medication could help with symptoms.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
This trial tests whether an immune-modulating drug can restart ovulation and improve fertility in women whose ovaries stopped working due to autoimmune disease. It is for women ages 18–38 with autoimmune premature ovarian insufficiency and certain antibodies.
This study tests whether a medication called rituximab can help people with psychotic symptoms that are linked to an autoimmune response (when the immune system attacks the brain). If you or your child have these antibodies, this treatment might reduce symptoms.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
Hear when a new Obsessive-Compulsive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.